Matthew T. Ballo, MD
Dr. Matt Ballo is a radiation oncologist and the founding chair and chief of Radiation Oncology at the College of Medicine at the University of Tennessee Health Science Center in Memphis, Tennessee. He is also an integral member of the leadership team of the West Cancer Center. His patient care includes the use of innovative radiation therapy tools for the treatment of both thoracic and abdominal cancers including malignant pleural and peritoneal mesothelioma and lung cancer. He is recognized for his expertise in head and neck radiation oncology, as well as his vision for designing a radiation oncology enterprise of tomorrow.[1] He has clinical experience with multiple radiation modalities and was integral in West Cancer Center having been the first center in the nation to offer tumor treating fields as part of a combination treatment for malignant pleural mesothelioma.[3]
Education and Career
Dr. Ballo received his Bachelor of Arts in biochemistry from Oberlin College in Oberlin, Ohio, and his medical degree from Case Western Reserve University School of Medicine in Cleveland. He completed his clinical internship at Mt. Sinai Medical Center in Cleveland and his clinical residency at The University of Texas MD Anderson Cancer Center in Houston, Texas.[1]
Following completion of his medical education and training, Dr. Ballo was a professor in the Department of Radiation Oncology at The University of Texas MD Anderson Cancer Center in Houston. He also served as an adjunct assistant professor of radiation therapy in the Department of Radiation Oncology there.
Professional Memberships and Activities
Dr. Ballo is a member of numerous professional organizations, including the American Society for Therapeutic Radiology and Oncology; the American College of Radiology; and the American Society of Clinical Oncology. In addition, he is a member of the editorial review board and guest editor of Breast Diseases: a Yearbook Quarterly. He is a journal reviewer for publications including the International Journal of Radiation Oncology, Biology, Physics; International Journal of Cancer; Radiotherapy & Oncology; The Lancet Oncology; and Head & Neck.[1]
Research
Dr. Ballo has published over 66 peer-reviewed, original research articles. His work also includes more than three dozen invited articles, editorials, abstracts, and book chapters.
Dr. Ballo’s recent publications include:[2]
Association of Tumor Treating Fields (TTFields) therapy with survival in newly diagnosed glioblastoma: a systematic review and meta-analysis. Ballo MT, Conlon P, Lavy-Shahaf G, Kinzel A, Vymazal J, Rulseh AM.J Neurooncol. 2023 Aug;164(1):1-9. doi: 10.1007/s11060-023-04348-w. Epub 2023 Jul 26.PMID: 37493865
Hypofractionation in Older Adults With Glioblastoma. Edmonston D, Vanderwalde N, Ballo M.Semin Radiat Oncol. 2022 Apr;32(2):168-171. doi: 10.1016/j.semradonc.2021.11.007.PMID: 35307119 Review. No abstract available.
Multi-Institutional Patterns of Use of Tumor-Treating Fields for Patients with Malignant Pleural Mesothelioma. Kutuk T, Walker JM, Ballo MT, Cameron RB, Alvarez JB, Chawla S, Luk E, Behl D, Dal Pra A, Morganstein N, Refaat T, Sheybani A, Squillante C, Zhang J, Kotecha R.Curr Oncol. 2023 May 23;30(6):5195-5200. doi: 10.3390/curroncol30060394.PMID: 37366877
The role of radiation therapy in the management of cutaneous malignancies. Part I: Diagnostic modalities and applications. Wilmas KM, Garner WB, Ballo MT, McGovern SL, MacFarlane DF.J Am Acad Dermatol. 2021 Sep;85(3):539-548. doi: 10.1016/j.jaad.2021.05.058. Epub 2021 Jun 8.PMID: 34116097 Review.
The role of radiation therapy in the management of cutaneous malignancies. Part II: When is radiation therapy indicated? Wilmas KM, Garner WB, Ballo MT, McGovern SL, MacFarlane DF.J Am Acad Dermatol. 2021 Sep;85(3):551-562. doi: 10.1016/j.jaad.2021.05.057. Epub 2021 Jun 8.PMID: 34116100 Review.
